PHA Accredits First Six PH Care Centers; Application Process Now Open
We are excited to announce that we have accredited our first six Pulmonary Hypertension Care Centers (PHCC). This initiative aims at improving overall quality of care and ultimately improving outcomes of patients with pulmonary hypertension.
Two types of centers will be accredited: Centers of Comprehensive Care (CCC) - the first six are listed below - and Regional Clinical Programs (RCP). For interested centers, the PHCC Application is now open and available for download. Many PH programs have already submitted their application, and you can track their progress on the Applicant Center page.
Quality Care from Experts in the Field
“The PHCC will give PH patients security in knowing they are receiving quality care from the experts in the field,” said Dr. Murali Chakinala, from the Washington University School of Medicine and PHCC Committee Chair. “Patients can feel confident that the PHCCs have been vetted by a rigorous process that includes a detailed application and a comprehensive site visit with ultimate adjudication by a Committee of more than 20 health professionals with vast experience in caring for PH patients.”
PHA's Scientific Leadership Council and the PHCC Oversight Committee set high parameters for PHCC accreditation. PHCC accreditation signifies that a PH program has demonstrated a dedication to making proper diagnosis and capacity to appropriately and comprehensively manage PH patients through a set of criteria established by the PHA Scientific Leadership Council – 28 global leaders in the field of pulmonary hypertension. These criteria have also been developed with input from many PH stakeholders including physicians, allied health care professionals, patients and PHA leadership and are considered essential to delivering high-quality care for these complex patients.
Patient Registry for Determining Effective Care
Accredited PH Care Centers will also contribute to a PH patient registry that will track diagnostic and treatment patterns at a national level, ultimately demonstrating quality improvement for the care of PH patients.
“The PH patient registry will provide important data on the care and outcomes of patients with pulmonary hypertension across the country,” said Dr. Steven Kawut of the Perelman School of Medicine at the University of Pennsylvania. “We can then begin to understand best practices in the treatment of PH and continue to improve the quality of life and survival of individuals with this disease.”
Linking Centers through a national network will increase collaboration in the PH community, through clinical, quality improvement and investigative partnership.
First Six Accredited Centers
- Inova Advanced Lung Disease and Transplant Program, Inova Fairfax Hospital, Fairfax, Va.
- Penn Pulmonary Hypertension / Pulmonary Vascular Disease Program, University of Pennsylvania Health System and Perelman School of Medicine, Philadelphia, Pa.
- Kentuckiana Pulmonary Associates, Louisville, Ky.
- UC Health Pulmonary Hypertension Program, University of Cincinnati, Cincinnati, Ohio.
- Cottage Pulmonary Hypertension Center, Cottage Health System, Santa Barbara, Calif.
- Stanford Pulmonary Hypertension Program, Stanford University, Stanford, Calif.
For more information on PHCC visit www.PHAssociation.org/PHCareCenters or email PHCC@PHAssociation.org.
Wednesday, October 01, 2014 1:44:00 PM
Screen Scleroderma Patients Annually for Pulmonary Hypertension
Scleroderma patients should be screened every year for pulmonary hypertension even if they are recently diagnosed and have no respiratory symptoms. Noninvasive tests can catch pulmonary problems early, and treatments are available to slow the progression of scleroderma. Read more and watch the video
Friday, September 19, 2014 1:42:00 PM
Researchers Find New Targets for Treating Pulmonary Hypertension
Jiwang Chen, research assistant professor of critical care medicine, sleep and allergy in the UIC College of Medicine, and his colleagues investigated the molecular mechanisms behind the abnormal proliferation of smooth muscle cells in the pulmonary artery and discovered two ways that the proliferation could be suppressed.
Dr. Chen as well as collaborating author Guofei Zhou have received research grants from PHA in the past. Dr. Roberto Machado, one of the senior authors, is a member of PHA's Scientific Leadership Council and is the PHA Medical Education On-Demand National Chair.
Wednesday, September 17, 2014 1:40:00 PM
CHEST Endorses Accreditation of PH Care Centers by PHA
The Pulmonary Hypertension Association and its Scientific Leadership Council have spearheaded a quality improvement initiative to accredit Pulmonary Hypertension Care Centers (PHCC) across the country. These centers are committed to providing high-quality care based on broadly accepted standards of care and consensus guidelines. These centers aspire to improve outcomes of patients with pulmonary hypertension. The American College of Chest Physicians (CHEST) has endorsed this accreditation process and sees it as another indicator of high quality care are for pulmonary hypertension patients.
“The PHCC are a testament to the growth in research and awareness of pulmonary hypertension,” said Rino Aldrighetti, PHA President and CEO. “We have grown from one treatment in 1996 to 12 in 2014, with more on the horizon. These centers prove that a small rare disease organization can save lives and move mountains in the race toward a cure.”
Currently there are six pilot centers
that have gone through the accreditation process. The online application process will open in mid-September 2014. For more information on PH Care Centers, go to www.PHCareCenters.org
Tuesday, September 09, 2014 1:38:00 PM
PHA Endorses CHEST Treatment Guidelines
The American College of Chest Physicians (CHEST) recently released guidelines for the management and treatment of pulmonary arterial hypertension (PAH) in adults, Pharmacological Therapy for Pulmonary Arterial Hypertension in Adults: CHEST Guideline and Expert Panel Report, in the CHEST Journal. The guidelines are free to view for clinicians, and provide the latest and most accurate treatment guidelines for PAH.
The Pulmonary Hypertension Association (PHA) endorses these guidelines and sees them as a step in the right direction. “Many times physicians are not clearly informed on the latest ways to treat PAH,” said Rino Aldrighetti, PHA President and CEO. “These guidelines help physicians understand the broad range of therapies available and the need for more research to create more.”
The CHEST Guideline and Expert Panel Report provides 79 recommendations and expert consensus statements aimed at assisting physicians in the management of PAH using the latest drug therapies. The guidelines were reviewed and endorsed by the PHA Scientific Leadership Council.
Read the guidelines
Thursday, August 28, 2014 4:27:00 PM